Minocycline has been shown to be neuroprotective in ischemic and neurodegenerative disease models and could potentially be relevant for clinical use. We revisited the hypothesis that minocycline acts through direct inhibition of calcium-induced mitochondrial permeability transition (mPT) resulting in reduced release of cytochrome c (cyt c). Minocycline, at high dosage, was found to prevent calcium-induced mitochondrial swelling under energized conditions similarly to the mPT inhibitor cyclosporin A (CsA) in rodent mitochondria derived from the CNS. In contrast to CsA, minocycline dose-dependently reduced mitochondrial calcium retention capacity (CRC) and respiratory control ratios and was ineffective in the de-energized mPT assay. Further, minocycline did not inhibit calcium-or tBid-induced cyt c release. We conclude that the neuroprotective mechanism of minocycline is likely not related to direct inhibition of mPT and propose that the mitochondrial effects of minocycline may contribute to toxicity rather than tissue protection at high dosing in animals and humans.
Introduction
Minocycline is a second-generation tetracycline derivative that has displayed neuroprotective properties in a broad range of models of neurological disease, e.g., global and focal ischemia, brain and spinal cord trauma, as well as Alzheimer's, Huntington's and Parkinson's disease (Arvin et al., 2002; Casarejos et al., 2006; Chen et al., 2000; Choi et al., 2005; Du et al., 2001; Festoff et al., 2006; Ryu et al., 2004; Sanchez Mejia et al., 2001; Teng et al., 2004; Yong et al., 2004; Yrjanheikki et al., 1998 Yrjanheikki et al., , 1999 . Furthermore, minocycline has prolonged life span in the most widespread model for amyotrophic lateral sclerosis (ALS), mice carrying a human mutation of superoxide dismutase (SOD) associated with familial ALS (Kriz et al., 2002; Van Den Bosch et al., 2002; Zhu et al., 2002) . The mechanisms of the neuroprotective action are currently unknown. Minocycline has been reported to influence the expression and activity of e.g. caspases and nitric oxide synthase, inhibit reactive microgliosis, induce the anti-apoptotic protein Bcl-2 and display antioxidant properties (Chen et al., 2000; Kraus et al., 2005; Tikka et al., 2001; Wang et al., 2004) .
Recently, several reports have concluded that mitochondria are key targets for the neuroprotective action of minocycline via direct inhibition of mitochondrial permeability transition (mPT) and the subsequent release of pro-apoptotic proteins from the intermembrane space (Teng et al., 2004; Wang et al., 2003; Zhu et al., 2002) . Inhibition of mPT is a feasible target for neuroprotection and its definition includes a sudden increase in permeability of the inner mitochondrial membrane leading to loss of electrochemical gradients and uncoupling of oxidative phosphorylation, overt mitochondrial swelling and release of Ca 2+ and intermembrane proteins such as cytochrome c (cyt c) to the surrounding cytosol (Halestrap et al., 2004) . The mPT inhibitor cyclosporin A (CsA) has exhibited neuroprotective properties when allowed to penetrate the blood-brain barrier in several animal models of ischemia, brain trauma and hypoglycemic coma (Friberg et al., 1998; Matsumoto et al., 1999; Sullivan et al., 2000; Uchino et al., 1998) . Inhibition of mPT may also prove to be a beneficial therapy for neurodegenerative diseases. Mitochondria from the spinal cord of transgenic ALS mice have been shown to have an impaired Ca 2+ retention capacity, possibly contributing to neuronal degeneration (Damiano et al., 2006) . Intrathecal administration of CsA to transgenic ALS mice www.elsevier.com/locate/ynbdi Neurobiology of Disease 25 (2007) 198 -205 
